Shares of Biogen Inc. BIIB slid 5.91% to $122.98 Friday, on what proved to be an all-around rough trading session for the ...

Argus analyst Jasper Hellweg downgraded Biogen (BIIB) to Hold from Buy.Don't Miss Our End of Quarter Offers: Discover the latest stocks ...

Biogen (BIIB) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to BIIB080, an investigational ...

Shares of Biogen Inc. BIIB shed 1.11% to $136.84 Monday, on what proved to be an all-around favorable trading session for the ...

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next few years, therapeutic companies ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other most undervalued biotech stocks to invest in. On February 21, Jared Holz, Mizuho Securities ...

In other Biogen news, Director Stephen A. Sherwin sold 8,760 shares of the company’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $150.02, for a ...

MLB, Topps and Nike have partnered to recognize baseball's elite performers from last season with custom gold-embellished MLB logos on their jerseys that will then be used to create trading cards.

Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure ...